novo nordisk cagrilintide Offers New Contender in Weight Management Novo Nordisk announces positive results

Nandoe Tewarie RDS, Hurtado A, Ritfeld GJ, Rahiem ST, Wendell DF, Barroso MMS, et al

Turned out that 90+% of the participants reported a physical benefit when taking 500 mcg in a Delayed Release capsule

The recommended starting point for finding UK trials is: NIHR Be Part of Research (bepartofresearch.nihr.ac.uk) the UK's public-facing portal for finding and joining clinical research studies ClinicalTrials.gov and the EU Clinical Trials Register international registries of ongoing studies, including the REDEFINE and TRIUMPH programmes Referral via a GP or specialist to a trial centre In the meantime, men with obesity or type 2 diabetes should be aware that NICE-approved treatments are already available and may offer meaningful clinical benefit: Semaglutide (Wegovy) is approved by NICE (TA875) for weight management in adults with a BMI 35 kg/m (or lower thresholds for certain ethnic groups) and at least one weight-related comorbidity, subject to specialist tier service criteria and duration requirements

Research References: Cagrilintide Amylin Analogue Research | Amylin Agonist Metabolic Studies Panda Peptide Quality Assurance: Every batch of Cagrilintide undergoes independent third-party HPLC and mass-spectrometry analysis before dispatch

Product identity is the one practical point worth emphasizing, because it is where the biggest gap between the trial and a vial opens up